PharmaBoardroom - Jean-Paul Clozel - CEO, Idorsia (October 2017)
J&J Makes Big Bet on Rare Disease With $30 Billion Actelion Deal - Bloomberg
Actelion Began in a Garage—Now Its Founding Couple Has $1 Billion and a New Biotech Firm - WSJ
Biotech: Jean-Paul Clozel kämpft bei Idorsia mit Gegenwind
Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) e Actelion CEO e fondatore Jean-Paul Clozel partecipano a una conferenza stampa presso la sede centrale di Actelion ad Allschwil, Svizzera, 26
Actelion: Die Knackpunkte eines Deals mit Johnson & Johnson | Tages-Anzeiger
J&J/Actelion: high pressure sale | Financial Times
Jean-Paul Clozel
Profile: Jean-Paul Clozel | Nature Biotechnology
Actelion's Jean-Paul Clozel aims to keep group's independence | Financial Times
How is Actelion Spin-Off Idorsia Doing One Year Later?
Actelion Could Boost Takeover Price for Johnson & Johnson
Clozel's CHF1bn Actelion Spin-Out Idorsia Awaits Janssen Buy-In :: Scrip
Actelion in $360M settlement - San Francisco Business Times
Jean-Paul Clozel, CEO Actelion - YouTube
Johnson & Johnson pays big for Swiss biotech firm Actelion | Euronews
Actelion never made offer for ZS Pharma: CEO
Actelion's Fate May Rest on Structure, Not Price, as Clozel Holds Firm - TheStreet
38 Jean Paul Clozel Photos and Premium High Res Pictures - Getty Images
Molecular Millionaire: Jean-Paul Clozel of Actelion
Actelion-Gründer ausgezeichnet – Berührende Würdigung eines Erfolgs-Teams | Basler Zeitung
Jean-Paul Clozel - CEO @ Idorsia - Crunchbase Person Profile
Jean-Paul Clozel
J&J Woos Billionaire Doctors Who Don't Need Cash in Actelion Bid - Bloomberg
Swiss biotech Actelion CEO Jean-Paul Clozel endorses independence not acquisition - CEOWORLD magazine
